Xencor Inc (NASDAQ:XNCR) – Investment analysts at Wedbush upped their FY2018 earnings per share (EPS) estimates for shares of Xencor in a report issued on Tuesday, November 6th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($1.48) per share for the year, up from their prior estimate of ($2.09). Wedbush currently has a “Outperform” rating and a $42.00 target price on the stock. Wedbush also issued estimates for Xencor’s Q4 2018 earnings at ($0.50) EPS, Q1 2019 earnings at ($0.41) EPS, Q2 2019 earnings at ($0.41) EPS, Q3 2019 earnings at ($0.42) EPS, Q4 2019 earnings at ($0.42) EPS, FY2019 earnings at ($1.67) EPS, FY2020 earnings at ($1.11) EPS, FY2021 earnings at ($1.63) EPS and FY2022 earnings at $0.64 EPS.

Several other equities analysts have also weighed in on XNCR. Zacks Investment Research raised Xencor from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Friday, August 10th. Canaccord Genuity boosted their price target on Xencor from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, August 8th. BidaskClub lowered Xencor from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Piper Jaffray Companies reissued an “overweight” rating on shares of Xencor in a research report on Tuesday, August 7th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $40.00 price target on shares of Xencor in a research report on Tuesday, November 6th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $41.13.

NASDAQ XNCR opened at $37.88 on Friday. The stock has a market capitalization of $2.34 billion, a PE ratio of -36.08 and a beta of 1.73. Xencor has a 1-year low of $19.50 and a 1-year high of $48.38.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.57. The firm had revenue of $29.04 million during the quarter.

In related news, insider Edgardo Baracchini, Jr. sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $40.16, for a total transaction of $2,008,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Paul A. Foster sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $46.03, for a total value of $1,841,200.00. Following the transaction, the insider now directly owns 44,952 shares in the company, valued at $2,069,140.56. The disclosure for this sale can be found here. Insiders have sold a total of 127,341 shares of company stock worth $5,390,865 over the last three months. 4.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in Xencor by 0.4% during the 3rd quarter. FMR LLC now owns 8,373,916 shares of the biopharmaceutical company’s stock worth $326,331,000 after purchasing an additional 30,163 shares during the last quarter. BlackRock Inc. increased its holdings in Xencor by 1.0% during the 3rd quarter. BlackRock Inc. now owns 4,051,683 shares of the biopharmaceutical company’s stock worth $157,896,000 after purchasing an additional 40,528 shares during the last quarter. Northern Trust Corp increased its holdings in Xencor by 22.3% during the 2nd quarter. Northern Trust Corp now owns 588,155 shares of the biopharmaceutical company’s stock worth $21,768,000 after purchasing an additional 107,128 shares during the last quarter. Artal Group S.A. increased its holdings in Xencor by 25.0% during the 3rd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $19,485,000 after purchasing an additional 100,000 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Xencor by 5.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 251,155 shares of the biopharmaceutical company’s stock worth $9,787,000 after purchasing an additional 12,320 shares during the last quarter. 83.03% of the stock is currently owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Read More: Capital Gains

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.